NRX Pharmaceuticals (NRXP) Long-Term Investments (2017 - 2026)

NRX Pharmaceuticals (NRXP) posted quarterly Long-Term Investments of $399000.0 for Q1 2026, up 0.5% quarter-over-quarter from $397000.0 in Q4 2025.

NRX Pharmaceuticals (NRXP) Long-Term Investments (2017 - 2026) Analysis & Trends

NRX Pharmaceuticals (NRXP) has reported Long-Term Investments for 7 consecutive years, with $399000.0 the latest figure, recorded in Q1 2026.

In Q1 2026, Long-Term Investments changed N/A year-over-year to $399000.0; the TTM figure through Mar 2026 stood at $399000.0 (changed N/A YoY), while the FY2025 annual figure was $397000.0, changed N/A from the prior year.
Long-Term Investments improved to $399000.0 in Q1 2026 per NRXP's latest filing, from $397000.0 in the prior quarter.
Across five years, Long-Term Investments topped out at $399000.0 in Q1 2026 and bottomed at $397000.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	5.79 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	9.83 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	1.77 Bn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	22.17 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	372.10 Mn
10	NRX Pharmaceuticals	132.53 Mn	105.83 Mn	426,000.00	402,000.00

Download Data